CoChat

Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer

Open access
Schiffmann, Lars Mortimer, Fritsch, Melanie, Gebauer, Florian, Günther, Saskia Diana, Stair, Neil Richard, Seeger, Jens Michael, Thangarajah, Fabinshy, Dieplinger, Georg, Bludau, Marc, Alakus, Hakan, Göbel, Heike, Quaas, Alexander, Zander, Thomas, Hilberg, Frank, Bruns, Christiane Josephine, Kashkar, Hamid, Coutelle, Oliver · 2019 · British Journal of Cancer
Cited by 79

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Immune infiltration is implicated in the development of acquired resistance to anti-angiogenic cancer therapy. We therefore investigated the correlation between neutrophil infiltration in metastasis of colorectal cancer (CRC) patients and survival after treatment with bevacizumab. Our study identifies CD177+ tumour neutrophil infiltration as an adverse prognostic factor for bevacizumab treatment. We further demonstrate that a novel anti-VEGF/anti-Ang2 compound (BI-880) can overcome resistance to VEGF inhibition in experimental tumour models. METHODS: A total of 85 metastatic CRC patients were stratified into cohorts that had either received chemotherapy alone (n = 39) or combined with bevacizumab (n = 46). Tumour CD177+ neutrophil infiltration was correlated to clinical outcome. The impact of neutrophil infiltration on anti-VEGF or anti-VEGF/anti-Ang2 therapy was studied in both xenograft and syngeneic tumour models by immunohistochemistry. RESULTS: The survival of bevacizumab-treated CRC patients in the presence of CD177+ infiltrates was significantly reduced compared to patients harbouring CD177- metastases. BI-880 treatment reduced the development of hypoxia associated with bevacizumab treatment and improved vascular normalisation in xenografts. Furthermore, neutrophil depletion or BI-880 treatment restored treatment sensitivity in a syngeneic tumour model of anti-VEGF resistance. CONCLUSIONS: Our findings implicate CD177 as a biomarker for bevacizumab and suggest VEGF/Ang2 inhibition as a strategy to overcome neutrophil associated resistance to anti-angiogenic treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-018-0198-3

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 79

Metadata

Authors
Schiffmann, L. M., Fritsch, M., Gebauer, F., Günther, S. D., Stair, N. R., Seeger, J. M., Thangarajah, F., Dieplinger, G., Bludau, M., Alakus, H., Göbel, H., Quaas, A., Zander, T., Hilberg, F., Bruns, C. J., Kashkar, H., & Coutelle, O.
Venue
British Journal of Cancer
Published
2018-10-31
Volume
120
Issue
1
Pages
69-78
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2899252841
Cited by
79
References
10
FWCI
2.12
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer. https://app.cochat.ai/papers/10.1038/s41416-018-0198-3
The paper
Schiffmann, L. M., Fritsch, M., Gebauer, F., Günther, S. D., Stair, N. R., Seeger, J. M., Thangarajah, F., Dieplinger, G., Bludau, M., Alakus, H., Göbel, H., Quaas, A., Zander, T., Hilberg, F., Bruns, C. J., Kashkar, H., & Coutelle, O. (2019). Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer. British Journal of Cancer. https://doi.org/10.1038/s41416-018-0198-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.